TRANSFORMING CANCER CARE: FUTURISTICALLY INTEGRATING PRECISION SURGERY AND COMPASSION-DRIVEN ONCOLOGY

Dr Arun Kumar Giri is a highly experienced surgical oncologist and robotic surgeon with over two decades of experience in advanced cancer care. Recognized for precision-driven cancer surgery, he specializes in minimally invasive and robotic techniques that improve outcomes and recovery.

- Dr Arun Kumar Giri, Director, Aakash Healthcare Super Speciality Hospital

He holds MBBS and MS from Banaras Hindu University and DNB in Surgical Oncology. He specializes in robotic and minimally invasive procedures for gastrointestinal, thoracic, breast, thyroid and gynecologic cancers. He trained in CRS/HIPEC (USA) and minimally invasive GI surgery (Japan) and is member of global surgical oncology societies.

There is a radical change in the field of cancer care. In the last twenty years, the cancer burden around the world has been rising steadily, with International Agency on Research on Cancer (IARC, GLOBOCAN 2020) estimating close to 20 million new cancer cases every year globally. In most malignancies, the survival has been greatly enhanced by the advances in diagnostics, surgical innovation, systemic therapies, and radiation methods.

Nevertheless, with the advances in technology, there is an increasing understanding that ideal cancer treatment should be deeply based not in accuracy alone but in empathy as well. The future of oncology is to achieve a smooth combination of precision surgery with patient-oriented and compassionate care which is state of the art.

The Evolution of Precision Surgery in Oncology

Precision surgery is a paradigm shift of radical anatomy-based resections to tumor-specific interventions, which are carefully planned. The presence of modern imaging modalities including high-resolution MRI, PET-CT, and intraoperative navigation systems facilitates a surgeon to establish the boundary of tumors with very high precision and accuracy. This has resulted in increased organ-sparing operation, decreased surgical morbidity and functional outcomes without jeopardizing oncologic safety.